Skip to main content
Erschienen in: World Journal of Surgery 5/2009

01.05.2009

Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience

verfasst von: Jeryong Kim, Jinsun Lee, Eilsung Chang, Seongmin Kim, Kwangsun Suh, Jiyoung Sul, Insang Song, Yonghoon Kim, Chuljoo Lee

Erschienen in: World Journal of Surgery | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

This study was designed to determine whether a preoperative fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with computed tomography (CT) (FDG-PET/CT) could be used as a guide for axillary node dissection (AND) or sentinel lymph node biopsy (SNB) in breast cancer patients.

Methods

Between February 2007 and April 2008, we performed FDG-PET/CT scans in 137 biopsy-proven breast cancer patients planning to have an SNB to select patients for either AND (PET/CT N+) or SNB (PET/CT N0). In performing SNB, we also performed additional non-SNB (ADD), which was enlarged at the lower axilla.

Results

Twenty-seven patients with positive scans underwent complete AND as a primary procedure, and 110 patients with negative scans underwent SNB + ADD. There were 8 cases of false negative scans, and no case of false positive scan. The overall sensitivity, specificity, positive predictive value, and overall accuracy of FDG-PET/CT in predicting axillary metastasis were 77.1%, 100%, 100%, and 94.2%, respectively. In a subset of 110 patients with SNB + ADD, 104 patients had histologically negative SN, and 6 patients had positive SN in frozen section. Among 110 SNB + ADD cases, there were only 8 cases (7.3%) of positive axillary basins in permanent biopsy, including two cases of late positives that had micrometastases in the SN only. Through selective SNB + ADD based on an FDG-PET/CT, we have spared 27 unnecessary SNBs (true positive scans).

Conclusions

FDG-PET/CT is a specific imaging modality for predicting axillary node metastasis, and allows for a selective approach to either AND or SNB. A selective SNB + ADD based on an FDG-PET/CT reduced both unnecessary SNBs and positive axillary basins, enhancing the identification rates of SN and the accuracy of SNB.
Literatur
1.
Zurück zum Zitat Carmichael AR (2008) A randomized controlled clinical trial on sentinel node lymph node dissection versus axillary lymph node dissection: a matter of technique or patient selection? Ann Surg 248:895–896PubMedCrossRef Carmichael AR (2008) A randomized controlled clinical trial on sentinel node lymph node dissection versus axillary lymph node dissection: a matter of technique or patient selection? Ann Surg 248:895–896PubMedCrossRef
2.
Zurück zum Zitat Krag D, Weaver D, Ashikaga T et al (1998) The sentinel node in breast cancer: a multicenter validation study. N Engl J Med 339:941–946PubMedCrossRef Krag D, Weaver D, Ashikaga T et al (1998) The sentinel node in breast cancer: a multicenter validation study. N Engl J Med 339:941–946PubMedCrossRef
3.
Zurück zum Zitat Lovrics PJ, Chen V, Coates G et al (2004) A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 11:846–853PubMedCrossRef Lovrics PJ, Chen V, Coates G et al (2004) A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 11:846–853PubMedCrossRef
4.
Zurück zum Zitat Kumar R, Jana S, Heiba SI et al (2003) Retrospective analysis of sentinel lymph node localization in multicentric palpable and non-palpable breast cancer. J Nucl Med 44:7–10PubMed Kumar R, Jana S, Heiba SI et al (2003) Retrospective analysis of sentinel lymph node localization in multicentric palpable and non-palpable breast cancer. J Nucl Med 44:7–10PubMed
5.
Zurück zum Zitat Wong SL, Edwards MJ, Chao C et al (2002) The effect of lymphatic tumor burden on sentinel lymph node biopsy results. Breast J 8:192–198PubMedCrossRef Wong SL, Edwards MJ, Chao C et al (2002) The effect of lymphatic tumor burden on sentinel lymph node biopsy results. Breast J 8:192–198PubMedCrossRef
6.
Zurück zum Zitat Vargas HI, Vargas MP, Venegas R et al (2003) Lymphatic tumor burden negatively impacts the ability to detect the sentinel lymph node in breast cancer. Am Surg 69:886–890PubMed Vargas HI, Vargas MP, Venegas R et al (2003) Lymphatic tumor burden negatively impacts the ability to detect the sentinel lymph node in breast cancer. Am Surg 69:886–890PubMed
7.
Zurück zum Zitat Keskek M, Balas S, Gokoz A et al (2006) Re-evaluation of axillary skip metastases in the era of sentinel lymph node biopsy in breast cancer. Surg Today 36:1047–1052PubMedCrossRef Keskek M, Balas S, Gokoz A et al (2006) Re-evaluation of axillary skip metastases in the era of sentinel lymph node biopsy in breast cancer. Surg Today 36:1047–1052PubMedCrossRef
8.
Zurück zum Zitat Shivers S, Cox C, Leight G et al (2002) Final results of the department of defense multicenter breast lymphatic mapping trial. Ann Surg Oncol 9:248–255PubMedCrossRef Shivers S, Cox C, Leight G et al (2002) Final results of the department of defense multicenter breast lymphatic mapping trial. Ann Surg Oncol 9:248–255PubMedCrossRef
9.
Zurück zum Zitat Reske SN, Kotzerke J (2001) FDG-PET for clinical use: results of the 3rd German Interdisciplinary Consensus Conference. “Onko-PET III”, 21 July and 19 September 2000. Eur J Nucl Med 28:1707–1723PubMedCrossRef Reske SN, Kotzerke J (2001) FDG-PET for clinical use: results of the 3rd German Interdisciplinary Consensus Conference. “Onko-PET III”, 21 July and 19 September 2000. Eur J Nucl Med 28:1707–1723PubMedCrossRef
10.
Zurück zum Zitat Kao CH, Hsieh JF, Tsai SC et al (2000) Comparison and discrepancy of 18F–2-deoxyglucose positron emission tomography and Tc-99 m MDP bone scan to detect bone metastasis. Anticancer Res 20:2189–2192PubMed Kao CH, Hsieh JF, Tsai SC et al (2000) Comparison and discrepancy of 18F–2-deoxyglucose positron emission tomography and Tc-99 m MDP bone scan to detect bone metastasis. Anticancer Res 20:2189–2192PubMed
11.
Zurück zum Zitat Kostakoglu L, Goldsmith SJ (2003) 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 44:224–239PubMed Kostakoglu L, Goldsmith SJ (2003) 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 44:224–239PubMed
12.
Zurück zum Zitat Eubank WB, Mankoff DA, Vesselle HJ et al (2002) Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 22:5–17PubMedCrossRef Eubank WB, Mankoff DA, Vesselle HJ et al (2002) Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 22:5–17PubMedCrossRef
13.
Zurück zum Zitat Bockisch A, Brandt-Mainz K, Gorges R et al (2003) Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca 30:22–25PubMedCrossRef Bockisch A, Brandt-Mainz K, Gorges R et al (2003) Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca 30:22–25PubMedCrossRef
14.
Zurück zum Zitat Ueda S, Tsuda H, Asakawa H et al (2008) Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer 8:165PubMedCrossRef Ueda S, Tsuda H, Asakawa H et al (2008) Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer 8:165PubMedCrossRef
15.
Zurück zum Zitat De Kanter AY, Van Eijck CHJ, Van Geel AN et al (1999) Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer. Br J Surg 86:1459–1462PubMedCrossRef De Kanter AY, Van Eijck CHJ, Van Geel AN et al (1999) Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer. Br J Surg 86:1459–1462PubMedCrossRef
16.
Zurück zum Zitat Sapino A, Cassoni P, Zanon E et al (2003) Ultrasonographically guided fine-needle aspiration of axillary lymph nodes: role in breast cancer management. Br J Cancer 88:702–706PubMedCrossRef Sapino A, Cassoni P, Zanon E et al (2003) Ultrasonographically guided fine-needle aspiration of axillary lymph nodes: role in breast cancer management. Br J Cancer 88:702–706PubMedCrossRef
17.
Zurück zum Zitat Motomura K, Inaji H, Komoike Y et al (2001) Gamma probe and ultrasonographically-guided fine-needle aspiration biopsy of sentinel lymph nodes in breast cancer patients. Eur J Surg Oncol 27:141–145PubMedCrossRef Motomura K, Inaji H, Komoike Y et al (2001) Gamma probe and ultrasonographically-guided fine-needle aspiration biopsy of sentinel lymph nodes in breast cancer patients. Eur J Surg Oncol 27:141–145PubMedCrossRef
18.
Zurück zum Zitat Kuenen-Boumeester V, Menke-Pluymers M, De Kanter AY et al (2003) Ultrasound-guided fine needle aspiration cytology of axillary lymph nodes in breast cancer patients. A preoperative staging procedure. Eur J Cancer 39:170–174 Kuenen-Boumeester V, Menke-Pluymers M, De Kanter AY et al (2003) Ultrasound-guided fine needle aspiration cytology of axillary lymph nodes in breast cancer patients. A preoperative staging procedure. Eur J Cancer 39:170–174
19.
Zurück zum Zitat Guller U, Nitzsche EU, Schipr U et al (2002) Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet! Breast Cancer Res Treat 71:171–173PubMedCrossRef Guller U, Nitzsche EU, Schipr U et al (2002) Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet! Breast Cancer Res Treat 71:171–173PubMedCrossRef
20.
Zurück zum Zitat Yang JH, Nam SJ, Lee TS et al (2001) Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients. Jpn J Clin Oncol 31:1–6PubMedCrossRef Yang JH, Nam SJ, Lee TS et al (2001) Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients. Jpn J Clin Oncol 31:1–6PubMedCrossRef
21.
Zurück zum Zitat Van der Hoeven JJ, Hoekstra OS, Comans EF et al (2002) Determinants of diagnostic performance of [F-18] fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 236:619–624PubMedCrossRef Van der Hoeven JJ, Hoekstra OS, Comans EF et al (2002) Determinants of diagnostic performance of [F-18] fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 236:619–624PubMedCrossRef
22.
Zurück zum Zitat Wahl RL, Siegel BA, Coleman RE et al (2004) Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the Staging Breast Cancer with PET Study Group. J Clin Oncol 22:277–285PubMedCrossRef Wahl RL, Siegel BA, Coleman RE et al (2004) Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the Staging Breast Cancer with PET Study Group. J Clin Oncol 22:277–285PubMedCrossRef
23.
Zurück zum Zitat Fehr MK, Hornung R, Varga Z et al (2004) Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 10:89–93PubMedCrossRef Fehr MK, Hornung R, Varga Z et al (2004) Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 10:89–93PubMedCrossRef
24.
Zurück zum Zitat Avril N, Rose CA, Schelling M et al (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18:3495–3502PubMed Avril N, Rose CA, Schelling M et al (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18:3495–3502PubMed
25.
Zurück zum Zitat Fournier K, Schiller A, Perry RR et al (2004) Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection. Ann Surg 239:859–863PubMedCrossRef Fournier K, Schiller A, Perry RR et al (2004) Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection. Ann Surg 239:859–863PubMedCrossRef
26.
Zurück zum Zitat Langer I, Marti WR, Guller U et al (2005) Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg 241:152–158PubMed Langer I, Marti WR, Guller U et al (2005) Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg 241:152–158PubMed
27.
Zurück zum Zitat Barranger E, Grahek D, Antoine M et al (2003) Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol 10:622–627PubMedCrossRef Barranger E, Grahek D, Antoine M et al (2003) Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol 10:622–627PubMedCrossRef
Metadaten
Titel
Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience
verfasst von
Jeryong Kim
Jinsun Lee
Eilsung Chang
Seongmin Kim
Kwangsun Suh
Jiyoung Sul
Insang Song
Yonghoon Kim
Chuljoo Lee
Publikationsdatum
01.05.2009
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 5/2009
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-009-9955-z

Weitere Artikel der Ausgabe 5/2009

World Journal of Surgery 5/2009 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.